InflaRx NV (FRA:IF0)
€ 1.35 0 (0%) Market Cap: 85.25 Mil Enterprise Value: 2.44 Mil PE Ratio: 0 PB Ratio: 0.89 GF Score: 32/100

InflaRx NV at HC Wainwright Investment Conference - New York Transcript

Sep 11, 2023 / 03:00PM GMT
Release Date Price: €3.8 (+2.29%)
Stephen Bersey
H.C. Wainwright & Co. - Equity Research Associate

Good day, everyone, and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Steve Bersey. I'm an equity research associate here at H.C. Wainwright and it's my pleasure to introduce Niels C. Riedemann, CEO of InflaRx. So I'll turn it over to Neils.

Niels C. Riedemann
InflaRx N.V. - CEO and Founder

Thank you so much, also for having us here today. We are happy to present. I'm here with our team Dr. Camilla Chong, our Chief Medical Officer, and Dr. Thomas Taapken, our CFO. So happy to go into the presentation right away. We had also some data released today, which I will spend a bit time on as well. So we're excited about that. But before I start, please take note of our corporate disclaimer, I'll be making forward-looking statements and also comparisons to published data of other molecules. So please take note of the disclaimer.

So when looking at our pipeline we are really in the terminal complement C5a, C5aR are spaced now with two very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot